Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III
Open access · greenAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.The Cochrane database of systematic reviews · 2025Pooled it
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.Breast cancer research : BCR · 2019Trial
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Trial
- Deciphering the Medicinal Chemistry Aspects of Akt Inhibitors for the Management of Cancer: Structure-Activity Relationship Frameworks, Landscapes, and Optimization Approaches.Chemistry & biodiversity · 2026Review
- AKT kinases as therapeutic targets.Journal of experimental & clinical cancer research : CR · 2024Review
- A targeted genetic modifier screen in Drosophila uncovers vulnerabilities in a genetically complex model of colon cancer.G3 (Bethesda, Md.) · 2023Article
- Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.Cancers · 2023Review
- Integrin αvβ3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer.Cancers · 2023Article
- Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.International journal of molecular sciences · 2023Review
- PI3K-AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds.Biomolecules · 2023Review
- Monocytes educated by cancer-associated fibroblasts secrete exosomal miR-181a to activate AKT signaling in breast cancer cells.Journal of translational medicine · 2022Article
- Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Review
- Review
- Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer.NPJ precision oncology · 2022Article
- Review
- Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.Exploration of targeted anti-tumor therapy · 2022Review
- Still no Rest for the Reductases: Ribonucleotide Reductase (RNR) Structure and Function: An Update.Sub-cellular biochemistry · 2022Review
- Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 1 institution in 1 country.
Cynthia X MaDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri. cynthiaxma@wustl.edu mjellis@bcm.edu.
Vera SumanDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Matthew P GoetzDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.
Donald NorthfeltDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Mark E BurkardDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Foluso AdemuyiwaDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Michael NaughtonDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Julie MargenthalerSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Rebecca AftSection of Endocrine and Oncologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Richard GrayDepartment of General Surgery, Mayo Clinic, Phoenix, Arizona.
Amye TevaarwerkDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Lee WilkeDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Tufia HaddadDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.
Timothy MoynihanDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.
Charles LoprinziDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.
Tina HiekenDepartment of General Surgery, Mayo Clinic, Rochester, Minnesota.
Erica K BarnellDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Zachary L SkidmoreMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.
Yan-Yang FengDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Kilannin KrysiakDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Jeremy HoogDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Zhanfang GuoDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Leslie NehringDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Kari B WisinskiDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Elaine MardisDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Ian S HagemannDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Kiran VijDivision of Oncology, Washington University School of Medicine, St. Louis, Missouri.
Souzan SanatiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Hussam Al-KatebDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Obi L GriffithDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Malachi GriffithDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Laurence DoyleCancer Therapy Evaluation Program, NCI, Bethesda, Maryland.
Charles ErlichmanDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.
Matthew J EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. cynthiaxma@wustl.edu mjellis@bcm.edu.
Mayo Clinic · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MWashington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MPhase 2 Clinical Trials Program for Experimental Therapeutics Clinical Trials NetworkUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ADJEI, ALEX A. · 2014 to 2019
$5.3MTargeting Aurora-A Kinase to Overcome Endocrine Resistance in ER+ Breast CancerR01CA214893 · NCI · MAYO CLINIC ROCHESTER · PI D'ASSORO, ANTONIO BONAVENTURA, HADDAD, TUFIA C · 2017 to 2021
$1.6MNCI NIH HHS P30 CA014520NCI NIH HHS P30 CA086862NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA214893NCI NIH HHS UM1 CA186686
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAnastrozoleAntineoplastic Combined Chemotherapy ProtocolsApoptosisBiomarkers, TumorBreast NeoplasmsCell ProliferationCentrifugation, Density GradientClass I Phosphatidylinositol 3-KinasesCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleHeterocyclic Compounds, 3-RingHumansNeoplasm StagingNitrilesAnastrozoleBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesHeterocyclic Compounds, 3-RingMK 2206NitrilesPIK3CA protein, humanProto-Oncogene Proteins c-aktReceptors, EstrogenTriazoles
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.